Insider Selling: The Oncology Institute, Inc. (NASDAQ:TOI) Director Sells 673,676 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Growth I. L.P. M33 sold 673,676 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $3.05, for a total value of $2,054,711.80. Following the sale, the director now directly owns 13,950,557 shares of the company's stock, valued at $42,549,198.85. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Oncology Institute Stock Up 7.5%

Shares of TOI stock traded up $0.20 on Wednesday, hitting $2.86. The stock had a trading volume of 1,872,237 shares, compared to its average volume of 1,008,406. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The business has a 50 day moving average of $2.59 and a 200 day moving average of $1.31. The Oncology Institute, Inc. has a 12-month low of $0.13 and a 12-month high of $3.50. The stock has a market cap of $255.21 million, a price-to-earnings ratio of -3.67 and a beta of 0.13.

Oncology Institute (NASDAQ:TOI - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%. The firm had revenue of $104.41 million during the quarter.

Analysts Set New Price Targets

Separately, BTIG Research started coverage on Oncology Institute in a research report on Thursday, May 15th. They issued a "buy" rating and a $7.00 price target for the company.

Hedge Funds Weigh In On Oncology Institute

Several institutional investors have recently modified their holdings of the business. Jane Street Group LLC boosted its position in Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after purchasing an additional 109,769 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Oncology Institute during the 4th quarter worth $41,000. Renaissance Technologies LLC raised its stake in shares of Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock worth $56,000 after purchasing an additional 12,000 shares during the period. XTX Topco Ltd boosted its holdings in shares of Oncology Institute by 49.5% in the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock worth $63,000 after buying an additional 18,448 shares during the last quarter. Finally, Citizens Financial Group Inc. RI bought a new position in Oncology Institute during the first quarter valued at about $71,000. 36.86% of the stock is owned by institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.